Released : Jan 25, 2017 12:00



Shire to announce full year 2016 results

Dublin, Ireland - January 25, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will
announce full year 2016 earnings on Thursday February 16, 2017.

Results press release will be      12:00 GMT / 07:00 EDT
issued at:

Investor conference call time:     14:00 GMT / 09:00 EDT

Live conference call for investors:

Flemming Ornskov, MD, Chief Executive Officer and Jeff Poulton, Chief Financial
Officer will host the investor and analyst conference call at 9:00 EDT / 14:00
GMT.

The details of the conference call are as follows:

UK dial in:                  0808 237 0030 or 020 3139 4830

US dial in:                  1 866 928 7517 or 1 718 873 9077

International Access         http://events.arkadin.com/ev/docs/
Numbers:                     NE_FEL_Events_International_Access_List.pdf

Password/Conf ID:            17162212#

Live Webcast:                investors.shire.com/quarterly-results/

Replay:

A replay of the presentation will be available for two weeks by phone and by
webcast for three months.  Replay information can be found on the Investor
Relations section of Shire's website at http://investors.shire.com/.

For further information please contact:

Investor Relations

Ian Karp                        ikarp@shire.com            +1 781 482 9018

Robert Coates                   rcoates@shire.com          +44 1256 894874

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We strive to
develop best-in-class products, many of which are available in more than 100
countries, across core therapeutic areas including Hematology, Immunology,
Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.



www.shire.com

Shire plc published this content on 25 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 January 2017 12:11:15 UTC.

Original documenthttp://otp.investis.com/clients/uk/shire/rns/regulatory-story.aspx?cid=1027&newsid=839101

Public permalinkhttp://www.publicnow.com/view/7481A51C8A7E898E4DA895129E4F6F24DA374AC7